Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Business Wire
Late-breaking poster from DUPLEX Study shows more FILSPARI® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g compared with irbesartan, correlating with reduced kidney failure risk in FSGSData presentations highlight biomarker and cardiovascular safety data from SPARTAN Study of FILSPARI in patients with IgAN SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, November 6-9.In focal segmental glomerulosclerosis (FSGS), the Company will present:A late-breaking analysis from the DUPLEX Study demonstrating that patients treated with FILSPARI® (sparsentan) were more likely to reach proteinuria levels under 0.7 g/g when compared with the maximum labeled dose of irbesartan, and achievement of this threshold correlated with reduced risk of kidney failure irrespective of treatment
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TVTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.MarketBeat
- Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA [Seeking Alpha]Seeking Alpha
- Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally [Yahoo! Finance]Yahoo! Finance
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/14/25 - Form SCHEDULE
- TVTX's page on the SEC website